2023
-
Early results on the A 055 POR trial
19 December 2023Vaccine Well Tolerated and Demonstrated Immunogenicity But Did Not Provide Protection Against TB Recurrence; Participants Being Informed; Further Analysis Continues
-
POR-TB Last participant last visit
18 April 2023